30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31481 ↗At a glance
Systematische Übersicht in Catheterization and Cardiovascular Interventions, 2025. Written by Andrea Erriquez and 9 co-authors. Institution: Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona, Ferrara, Italy. Major MEDLINE topics: Hemorrhage, Drug-Eluting Stents, Percutaneous Coronary Intervention, Sirolimus. Cited 1 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY 4.0). Funded by: The present analysis did not receive any economic support. However, Sahajanand Medical Technologies Ltd. (SMT) provided unrestricted funding for the conduction….
Abstract (original language)
Background
There is limited evidence on the safety and efficacy of biodegradable‐polymer sirolimus‐eluting ultra‐thin stent (BP‐SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
Aims
This study aims to evaluate the clinical outcomes of HBR patients treated with BP‐SES and ≤ 30‐day dual antiplatelet therapy (DAPT) regimen.
Methods
A systematic review was conducted to identify relevant studies involving HBR patients who underwent PCI with BP‐SES (Supraflex Cruz). Individual patient‐level data were extracted from the included studies. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or clinically driven target lesion revascularization at 1‐year. The safety endpoint was the 1‐year occurrence of Bleeding Academic Research Consortium (BARC) type 3−5.
Results
The study population included 1691 patients. Of these, 928 patients (55%) received a ≤ 30‐day DAPT, while 763 patients (45%) received a longer DAPT regimen. In the ≤ 30‐day DAPT group, primary outcome events occurred in 89 patients (9.5%, 95% CI: 7.7%−11.6%). The upper limit of the one‐sided 95% CI of 11.6% was below the pre‐specified non‐inferiority margin of 14%. There was no significant difference in the primary endpoint between the ≤ 30‐day DAPT group and the >30‐day DAPT group (propensity score adjusted HR: 0.95, 95% CI: 0.67−3). Notably, the incidence of BARC 3−5 bleeding events was significantly lower in the ≤ 30‐day DAPT group.
Conclusions
In HBR patients treated with BP‐SES, a ≤ 30‐day DAPT regimen is associated with a low rate of ischemic events and a significant reduction in major bleeding events. Trial Registration: PROSPERO CRD42024524208.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona, Ferrara, Italy.
- Department of Cardiology, Angiology and Intensive Care Medicine, Goethe University Hospital, Frankfurt, Germany.
- Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
- Cardiology Unit, Ospedale Maggiore, Bologna, Italy.
- Facharztpraxis Baldeney, Essen, Germany.
ORCID profiles: Gianluca Campo
Funding
- The present analysis did not receive any economic support. However, Sahajanand Medical Technologies Ltd. (SMT) provided unrestricted funding for the conduction…
Cite
APA
Erriquez, A., Leistner, D. M., Paradies, V., Pavasini, R., Serenelli, M., Casella, G., Biscaglia, S., Naber, C., Campo, G., & Smits, P. C. (2025). 30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31481
Vancouver
Erriquez A, Leistner DM, Paradies V, Pavasini R, Serenelli M, Casella G, et al. 30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31481
BibTeX
@article{Erriquez2025,
author = {Erriquez, Andrea and Leistner, David M and Paradies, Valeria and Pavasini, Rita and Serenelli, Matteo and Casella, Gianni and Biscaglia, Simone and Naber, Christoph and Campo, Gianluca and Smits, Pieter C},
title = {30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31481}
}
EUVIMED